vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Vir Biotechnology, Inc. is the larger business by last-quarter revenue ($240.0K vs $148.0K, roughly 1.6× ASTROTECH Corp). ASTROTECH Corp runs the higher net margin — -2653.4% vs -67975.4%, a 65322.0% gap on every dollar of revenue. On growth, ASTROTECH Corp posted the faster year-over-year revenue change (-43.3% vs -89.9%). ASTROTECH Corp produced more free cash flow last quarter ($-4.0M vs $-167.9M). Over the past eight quarters, ASTROTECH Corp's revenue compounded faster (-40.2% CAGR vs -88.0%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
ASTC vs VIR — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $240.0K |
| Net Profit | $-3.9M | $-163.1M |
| Gross Margin | 5.4% | — |
| Operating Margin | -2635.8% | -72267.9% |
| Net Margin | -2653.4% | -67975.4% |
| Revenue YoY | -43.3% | -89.9% |
| Net Profit YoY | 2.0% | 23.7% |
| EPS (diluted) | — | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | $240.0K | ||
| Q2 25 | $220.0K | $1.2M | ||
| Q1 25 | $534.0K | $3.0M | ||
| Q4 24 | $261.0K | $12.4M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $56.4M |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | $-163.1M | ||
| Q2 25 | $-2.9M | $-111.0M | ||
| Q1 25 | $-3.6M | $-121.0M | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | — | $-213.7M | ||
| Q2 24 | — | $-138.4M | ||
| Q1 24 | — | $-65.3M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | 99.1% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | -72267.9% | ||
| Q2 25 | -1326.4% | -9754.3% | ||
| Q1 25 | -724.2% | -4602.5% | ||
| Q4 24 | -1655.6% | — | ||
| Q3 24 | — | -9718.7% | ||
| Q2 24 | — | -5158.7% | ||
| Q1 24 | — | -142.0% |
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | -67975.4% | ||
| Q2 25 | -1331.8% | -9139.9% | ||
| Q1 25 | -680.3% | -3989.6% | ||
| Q4 24 | -1536.0% | — | ||
| Q3 24 | — | -8979.7% | ||
| Q2 24 | — | -4500.1% | ||
| Q1 24 | — | -115.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.17 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.88 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.56 | ||
| Q2 24 | — | $-1.02 | ||
| Q1 24 | — | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.5M | $796.1M |
| Total Assets | $19.7M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | $497.8M | ||
| Q2 25 | $15.1M | $598.7M | ||
| Q1 25 | $18.1M | $790.9M | ||
| Q4 24 | $21.5M | $901.0M | ||
| Q3 24 | — | $909.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | $796.1M | ||
| Q2 25 | $22.1M | $947.5M | ||
| Q1 25 | $24.8M | $1.0B | ||
| Q4 24 | $28.1M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | $1.0B | ||
| Q2 25 | $27.0M | $1.2B | ||
| Q1 25 | $27.5M | $1.3B | ||
| Q4 24 | $31.0M | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-167.6M |
| Free Cash FlowOCF − Capex | $-4.0M | $-167.9M |
| FCF MarginFCF / Revenue | -2671.6% | -69952.9% |
| Capex IntensityCapex / Revenue | 277.7% | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | $-167.6M | ||
| Q2 25 | $-2.4M | $-120.2M | ||
| Q1 25 | $-3.9M | $-78.1M | ||
| Q4 24 | $-3.0M | $-446.4M | ||
| Q3 24 | — | $-171.5M | ||
| Q2 24 | — | $-77.8M | ||
| Q1 24 | — | $-109.4M |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | $-167.9M | ||
| Q2 25 | $-2.7M | $-122.8M | ||
| Q1 25 | $-3.9M | $-79.7M | ||
| Q4 24 | $-3.4M | $-453.7M | ||
| Q3 24 | — | $-174.2M | ||
| Q2 24 | — | $-78.5M | ||
| Q1 24 | — | $-111.3M |
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | -69952.9% | ||
| Q2 25 | -1231.4% | -10111.8% | ||
| Q1 25 | -728.1% | -2630.1% | ||
| Q4 24 | -1288.5% | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | — | -197.4% |
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | 132.1% | ||
| Q2 25 | 158.2% | 209.1% | ||
| Q1 25 | 5.1% | 53.7% | ||
| Q4 24 | 122.2% | 59.0% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | — | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
